Cushing's syndrome Medical Services in China

Cushing's syndrome is a rare endocrine disorder characterized by chronic exposure to excessive levels of cortisol — a glucocorticoid hormone produced by the adrenal cortex. This hypercortisolism may arise from endogenous sources (e.g., pituitary adenoma causing Cushing’s disease, adrenal adenoma or carcinoma, or ectopic ACTH secretion) or exogenous causes (prolonged high-dose glucocorticoid therapy). Pathogenesis hinges on dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis: in Cushing’s disease (the most common endogenous form, accounting for ~70% of cases), a benign corticotroph adenoma secretes excess adrenocorticotropic hormone (ACTH), stimulating bilateral adrenal hyperplasia and cortisol overproduction. Adrenal tumors autonomously secrete cortisol independent of ACTH, while ectopic ACTH syndrome — often linked to small-cell lung cancer or neuroendocrine tumors — results in markedly elevated ACTH and cortisol with suppressed CRH and ACTH from the pituitary. Epidemiologically, Cushing’s syndrome affects approximately 1–2.5 per million people annually, with a female-to-male ratio of 3:1 and peak incidence between ages 20 and 50. Risk factors include long-term systemic corticosteroid use (e.g., for autoimmune diseases or transplant recipients), genetic predispositions (e.g., MEN1, PRKAR1A, or APC mutations in familial syndromes), obesity-related HPA axis dysregulation, and underlying neoplasms. Clinical manifestations are multisystemic: central obesity, moon facies, dorsocervical fat pad ('buffalo hump'), purple striae, thin skin with easy bruising, proximal muscle weakness, hypertension, glucose intolerance or overt diabetes mellitus, osteoporosis, menstrual irregularities, hirsutism, mood disturbances (depression, anxiety, cognitive fog), and increased susceptibility to infections. These features profoundly impair quality of life: patients report fatigue limiting daily function, body image distress due to visible stigmata, sexual dysfunction, social withdrawal, reduced work capacity, and heightened psychological burden — with studies showing significantly lower SF-36 physical and mental component scores compared to age-matched controls. Early diagnosis remains challenging due to symptom overlap with metabolic syndrome and depression; delayed recognition increases morbidity (e.g., cardiovascular events, vertebral fractures, opportunistic infections) and mortality. Multidisciplinary evaluation — including late-night salivary cortisol, 24-hour urinary free cortisol, low-dose dexamethasone suppression test, and dynamic imaging (pituitary MRI, adrenal CT/MRI, or PET-CT for ectopic sources) — is essential for accurate subtyping and treatment planning.

Cushing’s syndrome is a complex endocrine disorder characterized by chronic exposure to excess glucocorticoids—either endogenous (due to ACTH-dependent or ACTH-independent adrenal overproduction) or exogenous (iatrogenic, from prolonged corticosteroid therapy). Accurate etiological diagnosis is paramount before initiating treatment, as therapeutic strategies differ substantially across subtypes. Management is multidisciplinary, coordinated primarily by endocrinologists, with input from neurosurgeons, interventional radiologists, and oncologists when indicated.

Conservative treatment plays a critical supportive role, particularly in patients awaiting definitive intervention, those deemed medically unfit for surgery, or those with mild or fluctuating hypercortisolism. Lifestyle modification forms the cornerstone: caloric restriction with emphasis on low-glycemic-index carbohydrates, high-quality protein, and calcium/vitamin D supplementation to mitigate osteoporosis risk. Blood pressure control targets <130/80 mmHg using first-line agents such as ACE inhibitors or calcium channel blockers; antihypertensives with mineralocorticoid activity (e.g., spironolactone) are avoided due to potential interference with diagnostic testing. Glycemic management prioritizes insulin sensitizers (e.g., metformin) over sulfonylureas to reduce hypoglycemia risk; insulin may be required in severe cases. Regular weight-bearing exercise—under supervision—is encouraged to preserve muscle mass and bone mineral density, while minimizing fall risk. Psychological support—including cognitive behavioral therapy—is essential given the high prevalence of depression, anxiety, and cognitive impairment. Patients must also undergo rigorous ophthalmologic screening for glaucoma and cataracts, dermatologic evaluation for skin atrophy and striae progression, and baseline dual-energy X-ray absorptiometry (DXA) scanning.

Pharmacologic therapy serves three principal indications: preoperative cortisol reduction (to lower surgical morbidity), bridging therapy for inoperable or recurrent disease, and palliation in malignant ectopic ACTH-secreting tumors. First-line medical options include ketoconazole, a potent inhibitor of adrenal steroidogenesis (CYP11A1, CYP17, CYP21), dosed 200–1200 mg/day with liver enzyme monitoring. Mifepristone—a glucocorticoid receptor antagonist—is uniquely effective for controlling hypertension, hyperglycemia, and psychiatric symptoms in patients with cortisol resistance, though it does not lower serum cortisol levels and thus cannot be used for biochemical monitoring. Pasireotide, a multireceptor somatostatin analog with high affinity for sst5, is FDA-approved for Cushing’s disease refractory to surgery; it reduces ACTH and cortisol in ~25% of patients but carries significant risks of hyperglycemia (requiring concurrent antidiabetic therapy) and QT prolongation. Newer agents under active investigation include osilodrostat (a potent CYP11B1 inhibitor approved in the US/EU) and levoketoconazole (an enantiomer with improved hepatic safety). Medical therapy is rarely curative and requires close biochemical surveillance (late-night salivary cortisol, 24-hour urinary free cortisol) and clinical assessment every 4–6 weeks.

Surgical intervention remains the only potentially curative approach for most forms of endogenous Cushing’s syndrome. Transsphenoidal resection of pituitary corticotroph adenomas (Cushing’s disease) is the gold standard, with remission rates of 70–90% in experienced centers. Preoperative localization via high-resolution 3T MRI and bilateral inferior petrosal sinus sampling (IPSS) is mandatory for lateralization when MRI is inconclusive. For adrenal Cushing’s (adenoma, carcinoma, or primary bilateral macronodular hyperplasia), laparoscopic adrenalectomy is preferred, offering faster recovery and reduced complication rates versus open surgery. In cases of ectopic ACTH syndrome, surgical resection of the source tumor (e.g., bronchial carcinoid, thymic neuroendocrine tumor) is curative if localized and resectable. Bilateral adrenalectomy is reserved for persistent or recurrent Cushing’s disease unresponsive to repeat surgery, radiation, or medical therapy; however, it mandates lifelong glucocorticoid and mineralocorticoid replacement and carries a 10–20% risk of Nelson’s syndrome (progressive corticotroph tumor growth post-adrenalectomy).

Treatment in China offers distinct advantages rooted in infrastructure, expertise, and innovation. Major academic hospitals—including Peking Union Medical College Hospital, Shanghai Ruijin Hospital, and West China Hospital—host nationally accredited Endocrine Centers of Excellence with dedicated Cushing’s multidisciplinary teams. These centers perform over 300 transsphenoidal surgeries annually, achieving remission rates exceeding 85% for microadenomas. China has pioneered advances in intraoperative MRI-guided resection and real-time cortisol monitoring during surgery to optimize adenoma removal. The National Clinical Research Center for Metabolic Diseases supports large-scale prospective registries (e.g., China Cushing Registry), enabling rapid evidence generation. Moreover, domestically developed diagnostics—including highly sensitive LC-MS/MS assays for urinary free cortisol and salivary cortisol—have improved assay precision and accessibility across tier-2 and tier-3 hospitals. Cost-effectiveness is notable: surgical and medical therapies cost approximately 40–60% less than comparable care in Western high-income countries, without compromising quality metrics such as 30-day readmission (<2%) or perioperative mortality (<0.3%).

Post-treatment recovery demands structured, long-term follow-up. After successful surgery, patients require gradual glucocorticoid tapering over 6–18 months, guided by morning cortisol, ACTH, and clinical symptoms of adrenal insufficiency (fatigue, orthostasis, nausea). Lifelong annual screening for recurrence includes late-night salivary cortisol and dexamethasone suppression testing. All patients—regardless of etiology—must receive patient education on sick-day rules: doubling oral hydrocortisone doses during febrile illness or injury, carrying emergency injectable hydrocortisone, and wearing medical alert identification. Bone health maintenance continues indefinitely: bisphosphonates (e.g., zoledronic acid) are initiated if T-score ≤ −2.5 or after fragility fracture. Cardiovascular risk assessment (lipid panel, carotid intima-media thickness) is performed biannually. Psychosocial rehabilitation is integral; many patients experience persistent fatigue and cognitive deficits for 12–24 months post-remission, necessitating neuropsychological evaluation and graded return-to-work programs. Finally, genetic counseling is recommended for patients with bilateral adrenal disease, young-onset Cushing’s, or family history suggestive of MEN1, Carney complex, or PRKAR1A mutations. With comprehensive, individualized care spanning diagnosis through long-term surveillance, sustained remission and restoration of quality of life are achievable goals for the majority of patients with Cushing’s syndrome.